PRACTICAL NOTIONS REGARDING THE CONTRACTUAL PROVISION ON THE WARANTY AGAINST THE EVICTION OF SELLING CONTRACTS

The contractual provision on the warranty against eviction is a matter in which the parties involved in the making of a selling contract often have tight negotiations. Many times the seller is looking for the exemption of provision of warranty, but is such a clause legally available? In the following we will present you the procedure in which the parties can limit or extend the provision aginst eviction

Actualización en síndrome hemolítico urémico atípico: diagnóstico y tratamiento. Documento de consenso. Revisión

Podeu consultar la versió en castellà del document a: http://dx.doi.org/10.1016/j.nefro.2015.07.005Haemolytic uraemic syndrome (HUS) is a clinical entity defined as the triad of nonimmune haemolytic anaemia, thrombocytopenia, and acute renal failure, in which the underlying lesions are mediated by systemic thrombotic microangiopathy (TMA). Different causes can induce the TMA process that characterises HUS. In this document we consider atypical HUS (aHUS) a sub-type of HUS in which the TMA phenomena are the consequence of the endotelial damage in the microvasculature of the kidneys and other organs due to a disregulation of the activity of the complement system. In recent years, a variety of aHUs-related mutations have been identified in genes of the complement system, which can explain approximately 60% of the aHUS cases, and a number of mutations and polymorphisms have been functionally characterised. These findings have stablished that aHUS is a consequence of the insufficient regulation of the activation of the complement on cell surfaces, leading to endotelial damage mediated by C5 and the complement terminal pathway. Eculizumab is a monoclonal antibody that inhibits the activation of C5 and blocks the generation of the pro-inflammatory molecule C5a and the formation of the cell membrane attack complex. In prospective studies in patients with aHUS, the use of Eculizumab has shown a fast and sustained interruption of the TMA process and it has been associated with significative long-term improvements in renal function, the interruption of plasma therapy and important reductions in the need of dialysis. According to the existing literature and the accumulated clinical experience, the Spanish aHUS Group published a consensus document with recommendations for the treatment of aHUs (Nefrologia 2013;33[1]:27-45). In the current online version of this document, we update the aetiological classification of TMAs, the pathophysiology of aHUS, its differential diagnosis and its therapeutic management

Atypical Hemolytic Uremic Syndrome

SummaryHemolytic uremic syndrome (HUS) is a triad of microangiopathic hemolytic anemia, thrombocytopenia, and acute renal failure. The atypical form of HUS is a disease characterized by complement overactivation. Inherited defects in complement genes and acquired autoantibodies against complement regulatory proteins have been described. Incomplete penetrance of mutations in all predisposing genes is reported, suggesting that a precipitating event or trigger is required to unmask the complement regulatory deficiency. The underlying genetic defect predicts the prognosis both in native kidneys and after renal transplantation. The successful trials of the complement inhibitor eculizumab in the treatment of atypical HUS will revolutionize disease management

Pièges diagnostiques de la GEM idiopathique: à propos de trois cas

info:eu-repo/semantics/publishe

Development of PR3-positive ANCA vasculitis under treatment with Eculizumab for Atypical Hemolytic Uremic Syndrome: a case report

info:eu-repo/semantics/publishe

Additional file 2: of Hyponatremia is a marker of disease severity in HIV-infected patients: a retrospective cohort study

Risk factors for mortality of patients with CD4 < 200/μl in univariate/multivariate Cox’s proportional hazard models. Association of hyponatremia with mortality in a restricted population of patients who had advanced HIV disease with a CD4 count < 200/μl. (DOCX 52 kb

Additional file 1: of Hyponatremia is a marker of disease severity in HIV-infected patients: a retrospective cohort study

Main characteristics of patients lost to follow-up. Clinical and socio-demographic factors in patients lost to follow-up compared with patients not lost to follow-up. 1mean ± standard deviation; 2median (interquartile range); 3excluding patients hospitalized at first contact. (DOCX 92 kb

Diagnostic trap for Idiopathic Membranous Nephropathy: about 3 cases

info:eu-repo/semantics/nonPublishe

Additional file 3: of Hyponatremia is a marker of disease severity in HIV-infected patients: a retrospective cohort study

Causes of hospital admission in hyponatremic and normonatremic patients. Causes of hospital admission taking only into account the first admission per patient. (DOCX 68 kb